Climb Bio (CLYM) Preferred Dividend Payments (2020 - 2021)
Climb Bio's (CLYM) quarterly Preferred Dividend Payments came in at $1.3 million in Q3 2021, up 186.77% YoY from $461000.0 in Q3 2020, and down 38.25% on a QoQ basis from $2.1 million in Q2 2021.
Powered by 
Analysis
Climb Bio (CLYM) Preferred Dividend Payments (2020 - 2021) Analysis & Trends
Climb Bio (CLYM) has 2 years of Preferred Dividend Payments data on file, last reported at $1.3 million in Q3 2021.
- Quarterly Preferred Dividend Payments rose 186.77% year-over-year to $1.3 million in Q3 2021, while the trailing twelve-month figure through Jun 2022 was $1.3 million (down 71.39% YoY) and the FY2021 annual result came in at $4.5 million, up 99.04% from the prior year.
- Preferred Dividend Payments declined to $1.3 million in Q3 2021, from $2.1 million in the prior quarter.
- In the past five years, Preferred Dividend Payments ranged from a high of $2.1 million in Q2 2021 to a low of $452000.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Climb Bio | 1.17 Bn | 1.17 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 1.32 Mn |
| Jun 30, 2021 | 2.14 Mn |
| Mar 31, 2021 | 1.09 Mn |
| Dec 31, 2020 | 933,000.00 |
| Sep 30, 2020 | 461,000.00 |
| Jun 30, 2020 | 452,000.00 |